Krilogy Financial LLC Boosts Stake in Exact Sciences Co. (NASDAQ:EXAS)

Krilogy Financial LLC grew its stake in shares of Exact Sciences Co. (NASDAQ:EXASGet Rating) by 310.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,372 shares of the medical research company’s stock after buying an additional 13,139 shares during the quarter. Krilogy Financial LLC’s holdings in Exact Sciences were worth $684,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Itau Unibanco Holding S.A. raised its position in shares of Exact Sciences by 26.6% during the 4th quarter. Itau Unibanco Holding S.A. now owns 633 shares of the medical research company’s stock valued at $49,000 after buying an additional 133 shares in the last quarter. Prospera Financial Services Inc grew its holdings in shares of Exact Sciences by 5.1% during the 1st quarter. Prospera Financial Services Inc now owns 3,558 shares of the medical research company’s stock valued at $249,000 after purchasing an additional 174 shares during the last quarter. Koshinski Asset Management Inc. grew its holdings in shares of Exact Sciences by 45.5% during the 1st quarter. Koshinski Asset Management Inc. now owns 640 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 200 shares during the last quarter. Quantum Private Wealth LLC grew its holdings in shares of Exact Sciences by 0.4% during the 1st quarter. Quantum Private Wealth LLC now owns 61,248 shares of the medical research company’s stock valued at $4,282,000 after purchasing an additional 225 shares during the last quarter. Finally, Veritable L.P. grew its holdings in shares of Exact Sciences by 8.5% during the 1st quarter. Veritable L.P. now owns 2,923 shares of the medical research company’s stock valued at $204,000 after purchasing an additional 228 shares during the last quarter. Hedge funds and other institutional investors own 90.95% of the company’s stock.

Exact Sciences Trading Down 5.4 %

NASDAQ:EXAS opened at $34.35 on Friday. The company has a 50-day moving average price of $41.42 and a 200-day moving average price of $50.40. Exact Sciences Co. has a 12 month low of $34.16 and a 12 month high of $104.50. The company has a current ratio of 2.48, a quick ratio of 2.23 and a debt-to-equity ratio of 0.70. The stock has a market cap of $6.08 billion, a price-to-earnings ratio of -8.12 and a beta of 1.37.

Analysts Set New Price Targets

Several research firms recently commented on EXAS. StockNews.com raised shares of Exact Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 26th. Raymond James reduced their target price on shares of Exact Sciences from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Wednesday, August 3rd. Robert W. Baird cut their price target on shares of Exact Sciences from $90.00 to $75.00 and set an “outperform” rating on the stock in a report on Wednesday, August 3rd. Cowen cut their price target on shares of Exact Sciences from $83.00 to $67.00 and set an “outperform” rating on the stock in a report on Wednesday, August 3rd. Finally, Evercore ISI raised their price target on shares of Exact Sciences to $65.00 in a report on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $69.14.

Insider Transactions at Exact Sciences

In other news, Director Katherine S. Zanotti sold 4,608 shares of the firm’s stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total value of $208,005.12. Following the completion of the sale, the director now directly owns 60,318 shares of the company’s stock, valued at approximately $2,722,754.52. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Katherine S. Zanotti sold 4,608 shares of Exact Sciences stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the transaction, the director now directly owns 60,318 shares of the company’s stock, valued at approximately $2,722,754.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Katherine S. Zanotti sold 1,086 shares of Exact Sciences stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $40.13, for a total transaction of $43,581.18. Following the transaction, the director now directly owns 60,318 shares of the company’s stock, valued at $2,420,561.34. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,701 shares of company stock valued at $251,872. Company insiders own 1.30% of the company’s stock.

Exact Sciences Profile

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Further Reading

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASGet Rating).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.